



OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT

PA/PH/OMCL (07) 106 DEF

UNCERTAINTY OF MEASUREMENT - PART 2

Full document title and reference	Uncertainty of Measurement - Part 2 OMCL Policy on the Estimation and Application of Uncertainty in Analytical Measurement. To be used by OMCLs for activities other than compliance testing. PA/PH/OMCL (07) 106 DEF
Document type	Guideline
Legislative basis	-
Date of first adoption	May 2002
Date of original entry into force	January 2003
Date of entry into force of revised document	December 2007
Previous titles/other references	This document replaces document PA/PH/OMCL (2001) 7 DEF
Custodian Organisation	The present document was elaborated by OMCL Network/EDQM of the Council of Europe
Concerned Network	GEON

OMCL POLICY ON THE ESTIMATION AND APPLICATION OF UNCERTAINTY IN ANALYTICAL MEASUREMENT

To be used by OMCLs for activities other than compliance testing

1. INTRODUCTION

This document is intended to give guidance for the interpretation and application of ISO 17025 “General requirements for the testing and calibration laboratories”[1] and its pertinence to activities **other than** compliance testing performed in Official Medicines Control Laboratories (OMCL).

Measurement uncertainty is mentioned in ISO 17025 in several aspects and as described in a separate OMCL guidance [2].

The laboratory is to demonstrate that it has adequate knowledge of the contributions of all relevant aspects of the measurement process to the overall measurement uncertainty and that the laboratory has measures, in place, to keep these aspects under control as part of the quality policy. The laboratory may in this context be requested to give a quantitative indication of the uncertainty.

It should be noted that sampling, which may introduce a high degree of uncertainty, is not the responsibility of an OMCL and therefore results reported only relate to the specific sample.

2. OBJECTIVE

Investigation of suspicious samples is a statutory requirement in some countries and is performed in some OMCLs. The objective of this document is to give guidance on how to implement the ISO 17025 requirements dealing with the principles of measurement uncertainty for this type of testing.

3. SCOPE

This guidance is applicable to activities within the OMCL not related to compliance testing, such as investigation of suspicious samples. This includes testing of suspicious samples received for analysis by various clients (health authorities, customs, police, etc.). These samples are sometimes unique samples without indication of contents. Generally, testing which can be considered investigative and for which there are no pre-set performance characteristics or analytical acceptance criteria is covered by this guidance. Investigations based on the client's request are sometimes limited to determination of presence/absence and/or magnitude of a suspect ingredient rather than quantitative determination *strictu sensu*.

4. DEFINITION

The uncertainty of measurement “characterises the dispersion of the values that would be reasonably attributed to the measurand” [3].

5. ESTIMATION OF THE UNCERTAINTY OF MEASUREMENT

5.1. Introduction

This document relates to testing activities other than compliance testing. The extent of testing activities depends on the size of the sample, demand of the client - whether or not there is a need for a quantitative determination and, if so, the estimation of the measurement uncertainty of the results may or may not be required.

A number of steps in the analysis of the suspicious samples can be identified.

Step 1: Identification

Identification of component(s) of the sample using different methods (at least two independent methods).

Screening. A separation method like thin layer chromatography or liquid chromatography with DAD often gives an indication of what substance(s) may be present (tentative identification).

Confirmation. The presence of the substance(s) indicated during screening may be confirmed by a different chromatographic system. This might be thin layer chromatography, liquid chromatography or gradient liquid chromatography. Further information of the identity of the substance may be verified by a "spiking" experiment with DAD peak purity evaluation.

Specific test. When the presence of the substance(s) has been confirmed it may be necessary to perform a specific test like LC/MS for definitive identification.

Step 2a: Quantitative determination with authorised or other validated methods

The identified component (measurand) of the sample may be determined using an already validated method [2]. If there is no authorised method or validated method, which can be applied, then the procedure in Step 2b could be used.

Step 2b: Quantitative determination with methods adapted from authorised or other validated methods

The identified component in a pharmaceutical preparation, for which there is no authorised method or validated method, may be determined by a method described in the scientific literature or by modification of an authorised or validated method used for the determination of a similar compound.

-If sufficient amount of sample is available: A recovery experiment will be required and replicate determinations using a method where the standard uncertainty is estimated from the standard deviation.

-If not sufficient amount of sample is available: An approach based on historical data may be used (see 5.2.2).

